ARS Pharmaceuticals (SPRY) announced that ARS Pharma has filed for approval of neffy 2 mg in Canada and the United Kingdom, where it will be marketed as EURneffy, on behalf of its licensing partner, ALK- Abello A/S. neffy was recently approved in the U.S. for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh greater than or equal to30 kg. In November 2024, ARS Pharma announced a licensing agreement providing ALK with exclusive rights to commercialize neffy in Europe, Canada, United Kingdom and certain other geographies outside of the U.S.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRY:
- ARS Pharmaceuticals adds neffy to Commercial national formularies
- ARS Pharmaceuticals notes filings for neffy approval in China, Japan, Australia
- ARS Pharmaceuticals files for approval of neffy in China, Japan and Australia
- ARS Pharmaceuticals announces planned launch of neffyinSchools
- ARS Pharmaceuticals’ Strong Q3 2024 Highlights